Specific inhibition of the classical complement pathway with an engineered single-chain Fv to C1q globular heads decreases complement activation by apoptotic cells

Immunobiology

Volumn 215, Issue 5, 2010, Pages 395-405

  Duvall, Marcus R ^a   Hwang, Hee Young ^a   Boackle, R J ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Apoptosis; Classical complement pathway; Complement; Human C reactive protein (CRP); Inflammatory disease; Ischemia reperfusion injuries; Single chain Fv

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT MEMBRANE ATTACK COMPLEX; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

APOPTOSIS; ARTICLE; BINDING AFFINITY; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT FIXATION; COMPLEMENT INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN IMMOBILIZATION;

ANIMALS; ANTIBODY SPECIFICITY; APOPTOSIS; C-REACTIVE PROTEIN; CHO CELLS; COMPLEMENT C1Q; COMPLEMENT PATHWAY, CLASSICAL; CRICETINAE; CRICETULUS; DOWN-REGULATION; HUMANS; JURKAT CELLS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 77950925961     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2009.05.010     Document Type: Article

References (55)

1. Agrawal A. CRP after 2004. Molecular Immunology 2005, 42:927-930.
2. Arlaud G.J., Villiers C.L., Chesne S., Colomb M.G. Purified proenzyme C1r: some characteristics of its activation and subsequent proteolytic cleavage. Biochimica et Biophysica Acta 1980, 616:116-129.
3. Barrett T.D., Hennan J.K., Marks R.M., Lucchesi B.R. C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion. Journal of Pharmacology & Experimental Therapeutics 2002, 303:1007-1013.
4. Boackle R.J., Connor M.H., Vesely J. High molecular weight non-immunoglobulin salivary agglutinins (NIA) bind C1Q globular heads and have the potential to activate the first complement component. Molecular Immunology 1993, 30:309-319.
5. Boackle R.J., Johnson B.J., Caughman G.B. An IgG primary sequence exposure theory for complement activation using synthetic peptides. Nature 1979, 282:742-743.
6. Bradt B.M., Kolb W.P., Cooper N.R. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. Journal of Experimental Medicine 1998, 188:431-438.
7. Chen C.H., Boackle R.J. A newly discovered function for C1 inhibitor, removal of the entire C1qr2s2 complex from immobilized human IgG subclasses. [Erratum appears in Clin Immunol 1999 Feb;90(2):282]. Clinical Immunology & Immunopathology 1998, 87:68-74.
8. Chen C.H., Lam C.F., Boackle R.J. C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities. Immunology 1998, 95:648-654.
9. Cooper N.R. The classical complement pathway: activation and regulation of the first complement component. Advances in Immunology 1985, 37:151-216.
10. Ellison B.S., Zanin M.K., Boackle R.J. Complement susceptibility in glutamine deprived breast cancer cells. Cell Division 2007, 2:20.
11. Gaboriaud C., Juanhuix J., Gruez A., Lacroix M., Darnault C., Pignol D., Verger D., Fontecilla-Camps J.C., Arlaud G.J. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. Journal of Biological Chemistry 2003, 278:46974-46982.
12. Gershov D., Kim S., Brot N., Elkon K.B. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity.[Erratum appears in J Exp Med 2001 Jun 18;193(12):1439]. Journal of Experimental Medicine 2000, 192:1353-1364.
13. Giannakis E., Jokiranta T.S., Male D.A., Ranganathan S., Ormsby R.J., Fischetti V.A., Mold C., Gordon D.L. A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. European Journal of Immunology 2003, 33:962-969.
14. Griselli M., Herbert J., Hutchinson W.L., Taylor K.M., Sohail M., Krausz T., Pepys M.B. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. Journal of Experimental Medicine 1999, 190:1733-1740.
15. Groeneveld T.W., Ramwadhdoebe T.H., Trouw L.A., Ham D.L., Borden V., Drijfhout J.W., Hiemstra P.S., Daha M.R., Roos A. Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation. Molecular Immunology 2007, 44:3608-3614.
16. Hakobyan S., Harris C.L., Berg C.W., Fernandez-Alonso M.C., Jorge E.G., Cordoba S.R., Rivas G., Mangione P., Pepys M.B., Morgan B.P. Complement factor H binds to denatured rather than to native pentameric C-reactive protein. Journal of Biological Chemistry 2008, 283:30451-30460.
17. Hart M.L., Ceonzo K.A., Shaffer L.A., Takahashi K., Rother R.P., Reenstra W.R., Buras J.A., Stahl G.L. Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. Journal of Immunology 2005, 174:6373-6380.
18. Hwang H.Y., Duvall M.R., Tomlinson S., Boackle R.J. Highly specific inhibition of C1q globular-head binding to human IgG: A novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment. Molecular Immunology 2008, 45:2570-2580.
19. Jarva H., Jokiranta T.S., Hellwage J., Zipfel P.F., Meri S. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. Journal of Immunology 1999, 163:3957-3962.
20. Jiang H., Robey F.A., Gewurz H. Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain. Journal of Experimental Medicine 1992, 175:1373-1379.
21. Jiang H.X., Siegel J.N., Gewurz H. Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. Journal of Immunology 1991, 146:2324-2330.
22. Kaplan M.H., Volanakis J.E. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. Journal of Immunology 1974, 112:2135-2147.
23. Kerr F.K., Thomas A.R., Wijeyewickrema L.C., Whisstock J.C., Boyd S.E., Kaiserman D., Matthews A.Y., Bird P.I., Thielens N.M., Rossi V., Pike R.N. Elucidation of the substrate specificity of the MASP-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, C1-inhibitor. Molecular Immunology 2008, 45:670-677.
24. Kishore U., Reid K.B. Modular organization of proteins containing C1q-like globular domain. Immunopharmacology 1999, 42:15-21.
25. Kishore U., Zhang W., Corlett L., Waters P., Glaichenhaus N., Willcox N. Use of peptide: HLA class II complexes to study specific T cells in autoimmune myasthenia gravis. Annals of the New York Academy of Sciences 2003, 998:339-342.
26. Krijnen P.A., Nijmeijer R., Meijer C.J., Visser C.A., Hack C.E., Niessen H.W. Apoptosis in myocardial ischaemia and infarction. Journal of Clinical Pathology 2002, 55:801-811.
27. Laurell A.B., Martensson U., Sjoholm A.G. C1 dissociation: spontaneous generation in human serum of a trimer complex containing C1 inactivator, activated C1r, and zymogen C1s. Journal of Immunology 1987, 139:4145-4151.
28. McGrath F.D., Brouwer M.C., Arlaud G.J., Daha M.R., Hack C.E., Roos A. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. Journal of Immunology 2006, 176:2950-2957.
29. McMullen M.E., Hart M.L., Walsh M.C., Buras J., Takahashi K., Stahl G.L. Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. Immunobiology 2006, 211:759-766.
30. Mold C., Gewurz H. Inhibitory effect of C-reactive protein on alternative C pathway activation by liposomes and Streptococcus pneumoniae. Journal of Immunology 1981, 127:2089-2092.
31. Mold C., Gewurz H., Clos T.W. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999, 42:23-30.
32. Mold C., Kingzette M., Gewurz H. C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b. Journal of Immunology 1984, 133:882-885.
33. Nijmeijer R., Lagrand W.K., Visser C.A., Meijer C.J., Niessen H.W., Hack C.E. CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction?. International Immunopharmacology 2001, 1:403-414.
34. Ogden C.A., Kowalewski R., Peng Y., Montenegro V., Elkon K.B. IGM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity 2005, 38:259-264.
35. Peitsch M.C., Tschopp J., Kress A., Isliker H. Antibody-independent activation of the complement system by mitochondria is mediated by cardiolipin. Biochemical Journal 1988, 249:495-500.
36. Quartier P., Potter P.K., Ehrenstein M.R., Walport M.J., Botto M. Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. European Journal of Immunology 2005, 35:252-260.
37. Reid K.B., Porter R.R. Subunit composition and structure of subcomponent C1q of the first component of human complement. Biochemical Journal 1976, 155:19-23.
38. Rodriguez M., Lucchesi B.R., Schaper J. Apoptosis in myocardial infarction. Annals of Medicine 2002, 34:470-479.
39. Rossen R.D., Michael L.H., Hawkins H.K., Youker K., Dreyer W.J., Baughn R.E., Entman M.L. Cardiolipin-protein complexes and initiation of complement activation after coronary artery occlusion. Circulation Research 1994, 75:546-555.
40. Roumenina L.T., Ruseva M.M., Zlatarova A., Ghai R., Kolev M., Olova N., Gadjeva M., Agrawal A., Bottazzi B., Mantovani A., Reid K.B., Kishore U., Kojouharova M.S. Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry 2006, 45:4093-4104.
41. Saad A.F., Virella G., Chassereau C., Boackle R.J., Lopes-Virella M.F. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. Journal of Lipid Research 2006, 47:1975-1983.
42. Sarvari M., Vago I., Weber C.S., Nagy J., Gal P., Mak M., Kosa J.P., Zavodszky P., Pazmany T. Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity. Journal of Neuroimmunology 2003, 137:12-18.
43. Schumaker V.N., Hanson D.C., Kilchherr E., Phillips M.L., Poon P.H. A molecular mechanism for the activation of the first component of complement by immune complexes. Molecular Immunology 1986, 23:557-565.
44. Selkoe D.J., Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annual Review of Pharmacology & Toxicology 2003, 43:545-584.
45. Sellar G.C., Cockburn D., Reid K.B. Localization of the gene cluster encoding the A, B, and C chains of human C1q to 1p34.1-1p36.3. Immunogenetics 1992, 35:214-216.
46. Siegel J., Rent R., Gewurz H. Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. Journal of Experimental Medicine 1974, 140:631-647.
47. Singh S.K., Suresh M.V., Voleti B., Agrawal A. The connection between C-reactive protein and atherosclerosis. Annals of Medicine 2008, 40:110-120.
48. Sjoberg A.P., Trouw L.A., Clark S.J., Sjolander J., Heinegard D., Sim R.B., Day A.J., Blom A.M. The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. Journal of Biological Chemistry 2007, 282:10894-10900.
49. Trouw L.A., Okroj M., Kupreishvili K., Landberg G., Johansson B., Niessen H.W., Blom A.M. C4b-binding protein is present in affected areas of myocardial infarction during the acute inflammatory phase and covers a larger area than C3. PLoS ONE [Electronic Resource] 2008, 3.
50. Walsh M.C., Bourcier T., Takahashi K., Shi L., Busche M.N., Rother R.P., Solomon S.D., Ezekowitz R.A., Stahl G.L. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. Journal of Immunology 2005, 175:541-546.
51. Yonemasu K., Stroud R.M. Structural studies on human Clq: non-covalent and covalent subunits. Immunochemistry 1972, 9:545-554.
52. Zhang J., Wright W., Bernlohr D.A., Cushman S.W., Chen X. Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance. American Journal of Physiology Endocrinology & Metabolism 2007, 292.
53. Zhang M., Austen W.G., Chiu I., Alicot E.M., Hung R., Ma M., Verna N., Xu M., Hechtman H.B., Moore F.D., Carroll M.C. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:3886-3891.
54. Zhang M., Takahashi K., Alicot E.M., Vorup-Jensen T., Kessler B., Thiel S., Jensenius J.C., Ezekowitz R.A., Moore F.D., Carroll M.C. Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. Journal of Immunology 2006, 177:4727-4734.
55. Zwart B., Ciurana C., Rensink I., Manoe R., Hack C.E., Aarden L.A. Complement activation by apoptotic cells occurs predominantly via IgM and is limited to late apoptotic (secondary necrotic) cells. Autoimmunity 2004, 37:95-102.